These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 25491264)

  • 21. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Beadnall HN; Gill AJ; Riminton S; Barnett MH
    Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.
    Ouspid E; Razazian N; Moghadasi AN; Moradian N; Afshari D; Bostani A; Sariaslani P; Ansarian A
    Neurosciences (Riyadh); 2018 Apr; 23(2):129-134. PubMed ID: 29664454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
    Mukharesh L; Maloni H; Maiberger M; Chen W; Wallin M
    Clin Neurol Neurosurg; 2020 Aug; 195():105886. PubMed ID: 32470781
    [No Abstract]   [Full Text] [Related]  

  • 24. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
    Avasarala J; Jain S; Urrea-Mendoza E
    J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
    [No Abstract]   [Full Text] [Related]  

  • 25. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
    Walker S; Brew B
    J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Sharim J; Tashjian R; Golzy N; Pouratian N
    J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
    DiMarco JP; O'Connor P; Cohen JA; Reder AT; Zhang-Auberson L; Tang D; Collins W; Kappos L
    Mult Scler Relat Disord; 2014 Sep; 3(5):629-38. PubMed ID: 26265275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Pfender N; Jelcic I; Linnebank M; Schwarz U; Martin R
    Neurology; 2015 Jun; 84(23):2377-8. PubMed ID: 25957334
    [No Abstract]   [Full Text] [Related]  

  • 29. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sometimes less is more in multiple sclerosis drug switching.
    Costa BK; Sato DK
    Arq Neuropsiquiatr; 2016 Aug; 74(8):605-6. PubMed ID: 27556369
    [No Abstract]   [Full Text] [Related]  

  • 32. Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring.
    Tomohiko U; Mori M; Akiyuki U; Masuda S; Mutho M; Masuda H; Kuwabara S
    Br J Clin Pharmacol; 2015 Sep; 80(3):607-8. PubMed ID: 26077133
    [No Abstract]   [Full Text] [Related]  

  • 33. Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Physiol Rep; 2016 Sep; 4(17):. PubMed ID: 27624686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
    Hovi A; Airas L
    J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
    [No Abstract]   [Full Text] [Related]  

  • 35. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
    Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
    Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
    [No Abstract]   [Full Text] [Related]  

  • 36. Fingolimod-associated macular oedema.
    Jasani KM; Sharaf N; Rog D; Aslam T
    BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28619738
    [No Abstract]   [Full Text] [Related]  

  • 37. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
    Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
    Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
    Iljicsov A; Pál Z; Simó M
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
    J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.